Preliminary Form

News - Powered by Yahoo News

NMS Communications Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2008
NMS Communications Corporation (NASDAQ: NMSS), a leading provider of applications and platforms for value-added services in mobile telecommunications today announced preliminary financial results for the third quarter ended September 30, 2008 and is providing a business update on LiveWire Mobile.
Thu, 23 Oct 2008 20:34:19 GMT - (Centre Daily Times)

DJ DGAP-Adhoc: STRATEC presents preliminary figures for the first nine months of 2008
STRATEC Biomedical Systems AG / Quarter Results/Preliminary Results 23.10.2008 Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement.
Thu, 23 Oct 2008 10:51:46 GMT - (Financial.de)

NMS Communications Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2008
FRAMINGHAM, Mass.----NMS Communications Corporation , a leading provider of applications and platforms for value-added services in mobile telecommunications today announced preliminary financial results for the third quarter ended September 30, 2008 and is providing a business update on LiveWire Mobile.
Thu, 23 Oct 2008 20:05:00 GMT - (Business Wire via Yahoo! Finance)

ZIOPHARM Presents Darinaparsin Molecular Mechanism of Action and Preliminary Oral Administration Phase I Clinical Data ...
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that it presented darinaparsin (ZIO-101) mechanism of action data as well as preliminary data from Phase I studies with oral administration at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland.
Thu, 23 Oct 2008 11:49:34 GMT - (Centre Daily Times)

The New York Times Company Reports Preliminary Third-Quarter Results
NEW YORK----The New York Times Company announced today a preliminary third-quarter loss per share from continuing operations of $.01, including $.07 per share for severance costs, compared with $.10 earnings per share in the third quarter last year, which included $.02 per share for severance costs.
Thu, 23 Oct 2008 12:36:00 GMT - (Business Wire via Yahoo! Finance)

ZIOPHARM Presents Darinaparsin Molecular Mechanism of Action and Preliminary Oral Administration Phase I Clinical Data ...
GENEVA----ZIOPHARM Oncology, Inc. , announced today that it presented darinaparsin mechanism of action data as well as preliminary data from Phase I studies with oral administration at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland.
Thu, 23 Oct 2008 11:30:00 GMT - (Business Wire via Yahoo! Finance)

Allscripts Reports Preliminary Third Quarter 2008 Results
Allscripts-Misys Healthcare Solutions, Inc. today announced preliminary results for Allscripts Healthcare Solutions, Inc. for the three and nine months ended September 30, 2008. This is the last time Allscripts will report standalone AHS results.
Thu, 23 Oct 2008 10:00:00 GMT - (PR Newswire via Yahoo! Finance)

First Communications, Inc. and Renaissance Acquisition Corp. Jointly Announce Filing of Form S-4 Registration ...
First Communications, Inc. (AIM: FCOM) ("First Communications"), a leading Midwest competitive local exchange carrier and owner of wireless telecommunications towers, and Renaissance Acquisition Corp. (AMEX: RAK) ("Renaissance") today jointly announced that Renaissance has filed with the Securities and Exchange Commission a preliminary registration statement on Form S-4, which includes a proxy ...
Tue, 21 Oct 2008 17:20:19 GMT - (Centre Daily Times)

First Communications, Inc. and Renaissance Acquisition Corp. Jointly Announce Filing of Form S-4 Registration ...
AKRON, Ohio----First Communications, Inc. , a leading Midwest competitive local exchange carrier and owner of wireless telecommunications towers, and Renaissance Acquisition Corp. today jointly announced that Renaissance has filed with the Securities and Exchange Commission a preliminary registration statement on Form S-4, which includes a proxy statement/prospectus, in connection with the ...
Tue, 21 Oct 2008 17:06:00 GMT - (Business Wire via Yahoo! Finance)

JACC Intervention Publishes MIV's VESTASYNC I Trial Preliminary Results - Hydroxyapatite Non-Polymer-Based ...
MIV Therapeutics, Inc. (OTCBB: MIVI) (FRANKFURT: MIVN), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced that the Journal of the American College of Cardiology Intervention (JACC Intervention) published preliminary results from the VESTASYNC I trial.
Wed, 22 Oct 2008 11:26:33 GMT - (Medical News Today)

Posts